Ethyl methacrylate (EMA) is a colorless liquid monomer that is widely used in the production of acrylic polymers. It is synthesized through the esterification of methacrylic acid with ethanol. EMA is known for its excellent optical clarity, good adhesion, and high impact resistance. It is a key ingredient in many acrylic resins, paints, coatings, and adhesives. EMA is also used in the production of contact lenses, dental materials, and other biomedical applications. Its properties make it a valuable material in a variety of industries, and it is extensively studied to understand its polymerization kinetics, properties, and applications.'
ID Source | ID |
---|---|
PubMed CID | 7343 |
CHEMBL ID | 3182984 |
SCHEMBL ID | 15030 |
MeSH ID | M0066410 |
Synonym |
---|
2-propenoic acid, 2-methyl-, ethyl ester |
ethyl 2-methyl-2-propenoate |
nsc24152 |
nsc-24152 |
ethyl methylacrylate |
ethyl 2-methylacrylate |
ethyl .alpha.-methyl acrylate |
2-methylacrylic acid, ethyl ester |
wln: 2ovy1 & u1 |
methacrylic acid, ethyl ester |
97-63-2 |
rhoplex ac-33(rohm & haas) |
ethyl methacrylate |
inchi=1/c6h10o2/c1-4-8-6(7)5(2)3/h2,4h2,1,3h |
ethyl 2-methacrylate |
einecs 202-597-5 |
ethyl methacrylate monomer |
rhoplex ac-33 (rohm and haas) |
2-methyl-2-propenoic acid, ethyl ester |
ai3-25421 |
hsdb 1332 |
rhoplex ac-33 |
ccris 4817 |
ethyl alpha-methylacrylate |
brn 0471201 |
rcra waste no. u118 |
rcra waste number u118 |
un2277 |
ethylester kyseliny methakrylove [czech] |
nsc 24152 |
ethyl methacrylate, analytical standard |
ethyl methacrylate, contains 15-20 ppm monomethyl ether hydroquinone as inhibitor, 99% |
9003-42-3 |
ethyl 2-methylprop-2-enoate |
methacrylic acid ethyl ester |
M0084 |
NCGC00248838-01 |
AKOS005721173 |
tox21_200810 |
NCGC00258364-01 |
dtxsid1025308 , |
cas-97-63-2 |
dtxcid305308 |
BBL011403 |
STL146507 |
4-02-00-01523 (beilstein handbook reference) |
ec 202-597-5 |
ethylester kyseliny methakrylove |
80f70clt4o , |
ethyl methacrylate [un2277] [flammable liquid] |
unii-80f70clt4o |
SCHEMBL15030 |
ethyl methacrylate [inci] |
ethyl .alpha.-methylacrylate |
ethyl methacrylate [hsdb] |
light ester e |
ethyl 2-methylpropenoate |
2-methyl-2-propenoic acid ethyl ester |
un 2277 |
ethyl methacrylate contains 15-20 ppm monomethyl ether hydroquinone |
CHEMBL3182984 |
J-521265 |
mfcd00009161 |
ethyl methacrylate (stabilized with hq) |
ethyl methacrylate, (stabilized with hq) |
methacrylic acid-ethyl ester |
Q424811 |
26814-01-7 |
mfcd00084414 |
ethyl methacrylate resin, mw. 250.000 |
EN300-56282 |
Excerpt | Reference | Relevance |
---|---|---|
" Based on the available data on the formulation of nail products containing this ingredient, it is concluded that Ethyl Methacrylate is safe as used, when application is accompanied by directions for use as above." | ( Amended final report on the safety assessment of ethyl methacrylate. , 2002) | 0.31 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.0144 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
SMAD family member 2 | Homo sapiens (human) | Potency | 0.5132 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 0.5132 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (50.00) | 29.6817 |
2010's | 5 (35.71) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.68) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.14%) | 6.00% |
Case Studies | 1 (7.14%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |